Being locked down is no barrier for venture investors, apparently; private drug developers are awash with cash. Or at least some of them are: the second quarter saw a record $5.4bn raised by these start-ups, though the number of deals being done sits at decade lows.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,